Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded Randomized Study | NYU Langone Health

Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded Randomized Study

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Healthy People Who Were In Contact With Covid-9 Positive Person
Age: Between 18 years - 80 years
Gender: Male or Female

Other Inclusion Criteria:
1. Subjects who are willing and able to provide informed consent
2. Subjects who dad a close contact of a person with known PCR-confirmed SARS-CoV-2 infection or who is currently being assessed for COVID-19. Close contact defined as:
  - Household contact
  - Medical staff, first responders, or other care persons who cared for the person without personal protection
3. Subjects had less than 4 days since last contact with a person with SARS-CoV-2 infection
4. Subjects with body weight < 100 kg
5. Subjects who had access to device and internet for Telehealth visits

You may not be eligible for this study if the following are true:

1. Subjects with known hypersensitivity to HCQ or other 4-aminoquinoline compounds
2. Subjects currently hospitalized
3. Subjects with symptomatic with subjective fever, cough, or sore throat
4. Current medications exclude concomitant use of HCQ
5. Concomitant use of other anti-malarial treatment or chemoprophylaxis
6. Subjects with history of retinopathy of any etiology
7. Those who have psoriasis
8. Those who have porphyria
9. Subjects with known bone marrow disorders with significant neutropenia
10. Concomitant use of digoxin, cyclosporin, cimetidine, or tamoxifen
11. Subjects with known liver disease
12. Subjects with known long QT syndrome
13. Subjects who use any investigational or non-registered drug or vaccine within 30 days preceding the first dose of the study drugs, or planned use during the study period